Logo image of CTIC

CTI BIOPHARMA CORP (CTIC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CTIC - US12648L6011 - Common Stock

9.09 USD
0 (0%)
Last: 6/23/2023, 8:00:00 PM
9.09 USD
0 (0%)
After Hours: 6/23/2023, 8:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CTIC. CTIC was compared to 525 industry peers in the Biotechnology industry. CTIC may be in some trouble as it scores bad on both profitability and health. CTIC is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CTIC has reported negative net income.
  • In the past year CTIC has reported a negative cash flow from operations.
CTIC Yearly Net Income VS EBIT VS OCF VS FCFCTIC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

  • The profitability ratios for CTIC are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTIC Yearly ROA, ROE, ROICCTIC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K

1.3 Margins

  • CTIC has a better Gross Margin (94.11%) than 95.66% of its industry peers.
  • CTIC's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for CTIC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-1.05%
CTIC Yearly Profit, Operating, Gross MarginsCTIC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -200 -400 -600 -800 -1K

1

2. Health

2.1 Basic Checks

  • CTIC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CTIC has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for CTIC is higher compared to a year ago.
CTIC Yearly Shares OutstandingCTIC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
CTIC Yearly Total Debt VS Total AssetsCTIC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • CTIC has an Altman-Z score of -27.07. This is a bad value and indicates that CTIC is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of CTIC (-27.07) is worse than 88.59% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -27.07
ROIC/WACCN/A
WACC8.93%
CTIC Yearly LT Debt VS Equity VS FCFCTIC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

  • A Current Ratio of 1.27 indicates that CTIC should not have too much problems paying its short term obligations.
  • CTIC has a Current ratio of 1.27. This is amonst the worse of the industry: CTIC underperforms 84.24% of its industry peers.
  • A Quick Ratio of 1.26 indicates that CTIC should not have too much problems paying its short term obligations.
  • CTIC has a worse Quick ratio (1.26) than 83.28% of its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.26
CTIC Yearly Current Assets VS Current LiabilitesCTIC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 52.46% over the past year.
  • Looking at the last year, CTIC shows a very strong growth in Revenue. The Revenue has grown by 3201.48%.
  • CTIC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.49% yearly.
EPS 1Y (TTM)52.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.97%
Revenue 1Y (TTM)3201.48%
Revenue growth 3Y152.53%
Revenue growth 5Y16.49%
Sales Q2Q%950.81%

3.2 Future

  • The Earnings Per Share is expected to grow by 31.18% on average over the next years. This is a very strong growth
  • CTIC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 57.28% yearly.
EPS Next Y66.63%
EPS Next 2Y57.35%
EPS Next 3Y40.69%
EPS Next 5Y31.18%
Revenue Next Year121.03%
Revenue Next 2Y111.79%
Revenue Next 3Y81.8%
Revenue Next 5Y57.28%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CTIC Yearly Revenue VS EstimatesCTIC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
CTIC Yearly EPS VS EstimatesCTIC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CTIC. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 22.47, which indicates a rather expensive current valuation of CTIC.
  • Based on the Price/Forward Earnings ratio, CTIC is valued cheaper than 95.34% of the companies in the same industry.
  • CTIC's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.26.
Industry RankSector Rank
PE N/A
Fwd PE 22.47
CTIC Price Earnings VS Forward Price EarningsCTIC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTIC Per share dataCTIC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • CTIC's earnings are expected to grow with 40.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.35%
EPS Next 3Y40.69%

0

5. Dividend

5.1 Amount

  • CTIC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CTI BIOPHARMA CORP / CTIC FAQ

What is the fundamental rating for CTIC stock?

ChartMill assigns a fundamental rating of 3 / 10 to CTIC.


What is the valuation status for CTIC stock?

ChartMill assigns a valuation rating of 3 / 10 to CTI BIOPHARMA CORP (CTIC). This can be considered as Overvalued.


What is the profitability of CTIC stock?

CTI BIOPHARMA CORP (CTIC) has a profitability rating of 1 / 10.


What is the financial health of CTI BIOPHARMA CORP (CTIC) stock?

The financial health rating of CTI BIOPHARMA CORP (CTIC) is 1 / 10.